Rebecca Snow

Rebecca Snow supports clients in market access, product commercialization, and reimbursement strategy.

She applies her experience in economics and public policy to help clients to successfully navigate the complex competitive landscape.

Prior to joining Avalere, Rebecca was the senior research specialist dedicated to Mylan Pharmaceuticals’ Global Policy department. In addition to providing research support on all aspects of global policy, she assisted company decision-making with SMEs on a broad range of topics including emerging infectious diseases, antimicrobial resistance, drug shortages, and the global supply chain. Previously, Rebecca worked with a former Federal Trade Commission policy director in private practice, advising consumer and provider associations as well as congressional offices and committees on healthcare antitrust and competition policy.

Rebecca holds a BS in resource economics from the University of Massachusetts Amherst. She will graduate with an MBA from Georgetown University in 2021.

Authored Content

As the COVID-19 pandemic draws to a close in the US, another public health concern is once again coming to the fore: antimicrobial resistance (AMR).

Since the beginning of the Public Health Emergency (PHE), manufacturers have been developing monoclonal antibodies (mAbs) and other treatment modalities to prevent and treat COVID-19.